Recognizing ADHD in adults with comorbid mood disorders: Implications for identification and management

Postgraduate Medicine

Volumn 121, Issue 5, 2009, Pages 31-41

  Goodman, David W ^a,b   Thase, Michael E ^c  

^a John Hopkins   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

ADHD; Adults; Comorbidity; Mood disorders

Indexed keywords

AMFEBUTAMONE; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; DESIPRAMINE; DEXAMPHETAMINE; FLUOXETINE; MOOD STABILIZER; NEUROLEPTIC AGENT; PAROXETINE; PLACEBO; PSYCHOSTIMULANT AGENT; SERTRALINE; VENLAFAXINE;

ACADEMIC ACHIEVEMENT; ADULT; ADULTHOOD; ALGORITHM; ARTICLE; ATTENTION DEFICIT DISORDER; BIPOLAR DISORDER; CLINICAL PRACTICE; COMORBIDITY; DEPRESSION; HUMAN; HUMAN RELATION; INFORMATION RETRIEVAL; JOB PERFORMANCE; MAJOR DEPRESSION; MEDLINE; MOOD DISORDER; PRACTICE GUIDELINE; PREVALENCE; QUALITY OF LIFE; SELF ESTEEM; SYMPTOM; TREATMENT OUTCOME; TREATMENT PLANNING;

EID: 78649272687     PISSN: 00325481     EISSN: 19419260     Source Type: Journal    
DOI: 10.3810/pgm.2009.09.2049     Document Type: Article

References (67)

1. Still GF. Some abnormal psychical conditions in children: the Goulstonian lectures. Lancet. 1902;1:1008-1012.
2. Wood DR, Reimherr FW, Wender PH, Johnson GE. Diagnosis and treatment of minimal brain dysfunction in adults: a preliminary report. Arch Gen Psychiatry. 1976;33(12):1453-1460.
3. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington, DC: American Psychiatric Association; 1994.
4. Bloom B, Cohen RA. Summary health statistics for U.S. children: National Health Interview Survey, 2006. Vital Health Stat 10. 2007; (234): 1-79.
5. Visser SN, Lesesne CA, Perou R. National estimates and factors associated with medication treatment for childhood attention-deficit/hyperactivity disorder. Pediatrics. 2007;119(suppl 1):S99-S106.
6. Faraone SV, Sergeant J, Gillberg C, Biederman J. The worldwide prevalence of ADHD: is it an American condition? World Psychiatry. 2003;2(2):104-113.
7. Weiss M, Hechtman LT, Weiss G. ADHD in Adulthood: A Guide to Current Theory, Diagnosis, and Treatment. Baltimore, MD: Johns Hopkins University Press; 1999.
8. Kessler RC, Adler LA, Barkley R, et al. Patterns and predictors of attention-deficit/hyperactivity disorder persistence into adulthood: results from the national comorbidity survey replication. Biol Psychiatry. 2005;57(11):1442-1451. (Pubitemid 40798566)
9. Barkley RA, Murphy KR, Fischer M. ADHD in Adults: What the Science Says. New York, NY: Guilford Press; 2008.
10. Dulcan M. Practice parameters for the assessment and treatment of children, adolescents, and adults with attention-deficit/hyperactivity disorder. American Academy of Child and Adolescent Psychiatry. J Am Acad Child Adolesc Psychiatry. 1997;36(suppl 10):85S-121S.
11. Faraone SV, Biederman J, Mick E. The age-dependent decline of attention deficit hyperactivity disorder: a meta-analysis of follow-up studies. Psychol Med. 2006;36(2):159-165. (Pubitemid 43126140)
12. Faraone SV, Biederman J, Spencer T, et al. Attention-deficit/ hyperactivity disorder in adults: an overview. Biol Psychiatry. 2000;48(1):9-20.
13. Faraone SV, Perlis RH, Doyle AE, et al. Molecular genetics of attention-deficit/hyperactivity disorder. Biol Psychiatry. 2005;57(11):1313- 1323. (Pubitemid 40798551)
14. Shaw P, Eckstrand K, Sharp W, et al. Attention-deficit/hyperactivity disorder is characterized by a delay in cortical maturation. Proc Natl Acad Sci U S A. 2007;104(49):19649-19654.
15. Faraone SV. Etiology and pathophysiology of adult attention-deficit/ hyperactivity disorder. Prim Psychiatry. 2004;11:28-40.
16. Adler L, Cohen J. Diagnosis and evaluation of adults with attention-deficit/hyperactivity disorder. Psychiatr Clin North Am. 2004;27(2):187-201.
17. Goodman DW. The consequences of attention-deficit/hyperactivity disorder in adults. J Psychiatr Pract. 2007;13(5):318-327.
18. Weiss MD, Weiss JR. A guide to the treatment of adults with ADHD. J Clin Psychiatry. 2004;65(suppl 3):27-37.
19. Kessler RC, Adler L, Barkley R, et al. The prevalence and correlates of adult ADHD in the United States: results from the National Comorbidity Survey Replication. Am J Psychiatry. 2006;163(4):716-723.
20. Fayyad J, De Graaf R, Kessler R, et al. Cross-national prevalence and correlates of adult attention-deficit hyperactivity disorder. Br J Psychiatry. 2007;190:402-409.
21. Nierenberg AA, Miyahara S, Spencer T, et al; STEP-BD Investigators. Clinical and diagnostic implications of lifetime attention-deficit/hyperactivity disorder comorbidity in adults with bipolar disorder: data from the first 1000 STEP-BD participants. Biol Psychiatry. 2005;57(11):1467-1473.
22. Alpert JE, Maddocks A, Nierenberg AA, et al. Attention deficit hyperactivity disorder in childhood among adults with major depression. Psychiatry Res. 1996;62(3):213-219. (Pubitemid 26189427)
23. Schubiner H, Tzelepsis A, Milberger S, et al. Prevalence of attention-deficit/hyperactivity disorder and conduct disorder among substance abusers. J Clin Psychiatry. 2000;61(4):244-251.
24. Van Ameringen M, Mancini C, Patterson B, Simpson W, Freeman W. Adult attention-deficit/hyperactivity disorder: prevalence in an anxiety disorders clinic population. Paper presented at: the 2008 Annual Conference of the Anxiety Disorders Association 28th Annual Meeting; March 2008; Savannah, GA.
25. de Graaf R, Kessler RC, Fayyad J, et al. The prevalence and effects of adult attention-deficit/hyperactivity disorder (ADHD) on the performance of workers: results from the WHO World Mental Health Survey Initiative. Occup Environ Med. 2008;65(12):835-842.
26. Castle L, Aubert RE, Verbrugge RR, Khalid M, Epstein RS. Trends in medication treatment for ADHD. J Atten Disord. 2007;10(4):335-342.
27. Murphy KR, Barkley RA, Bush T. Young adults with attention deficit hyperactivity disorder: subtype differences in comorbidity, educational, and clinical history. J Nerv Ment Dis. 2002;190(3):147-157.
28. Biederman J, Faraone SV, Spencer TJ, Mick E, Monuteaux MC, Aleardi M. Functional impairments in adults with self-reports of diagnosed ADHD: A controlled study of 1001 adults in the community. J Clin Psychiatry. 2006;67(4):524-540. (Pubitemid 43764229)
29. Able SL, Johnston JA, Adler LA, Swindle RW. Functional and psychosocial impairment in adults with undiagnosed ADHD. Psychol Med. 2007;37(1):97-107.
30. Biederman J, Faraone SV, Spencer T, et al. Patterns of psychiatric comorbidity, cognition, and psychosocial functioning in adults with attention deficit hyperactivity disorder. Am J Psychiatry. 1993;150(12):1792-1798.
31. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders DSM-IV-TR (Text Revision). Arlington, VA: American Psychiatric Association; 2000.
32. Shekim WO, Asamow RF, Hess E, Zaucha K, Wheeler N. A clinical and demographic profile of a sample of adults with attention deficit hyperactivity disorder, residual state. Compr Psychiatry. 1990;31(5):416-425. (Pubitemid 20305300)
33. Sobanski E, Brüggemann D, Alm B, et al. Psychiatric comorbidity and functional impairment in a clinically referred sample of adults with attention-deficit/hyperactivity disorder (ADHD). Eur Arch Psychiatry Clin Neurosci. 2007;257(7):371-377.
34. Secnik K, Swensen A, Lage MJ. Comorbidities and costs of adult patients diagnosed with attention-deficit hyperactivity disorder. Pharmacoeconomics. 2005;23(1):93-102.
35. Eyestone LL, Howell RJ. An epidemiological study of attention-deficit hyperactivity disorder and major depression in a male prison population. Bull Am Acad Psychiatry Law. 1994;22(2):181-193.
36. Hinnenthal JA, Perwien AR, Sterling KL. A comparison of service use and costs among adults with ADHD and adults with other chronic diseases. Psychiatr Serv. 2005;56(12):1593-1599.
37. Fishman PA, Stang PE, Hogue SL. Impact of comorbid attention deficit disorder on the direct medical costs of treating adults with depression in managed care. J Clin Psychiatry. 2007;68(2):248-253.
38. Sheehan DV, Lecrubier Y, Sheehan KH, et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry. 1998;59(suppl 20):22-33.
39. Winokur G, Coryell W, Endicott J, Akiskal H. Further distinctions between manic-depressive illness (bipolar disorder) and primary depressive disorder (unipolar depression). Am J Psychiatry. 1993;150(8):1176-1181. (Pubitemid 23218897)
40. Adler LA, Maya E, Sitt D, Dostal P. Issues in the treatment and diagnosis of ADHD by primary care physicians. Presented at: the American Psychiatric Association Annual Meeting; May 2006; Toronto, ON.
41. Goodman D. Treatment and assessment of ADHD in adults. In: Biederman J, ed. ADHD Across the Lifespan: An Evidence-Based Understanding From Research to Clinical Practice. Hasbrouck Heights, NJ: Veritas Institute for Medical Education, Inc and MedLearning, Inc; 2006:227-270.
42. Murphy KR, Adler LA. Assessing a Mention-deficit/hyperactivity disorder in adults: focus on rating scales. J Clin Psychiatry. 2004;65(suppl 3):12-17.
43. Montano B. Diagnosis and treatment of ADHD in adults in primary care. J Clin Psychiatry. 2004;65(suppl 3):18-21.
44. Adderall XR [package insert]. Wayne, PA: Shire US, Inc; 2008.
45. Concerta [package insert]. Mountain View, CA: ALZA Corporation; 2008.
46. Focalin XR [package insert]. East Hanover, NJ: Novartis Pharmaceutical Corp; 2008.
47. Strattera [package insert]. Indianapolis, IN: Eli Lilly & Co; 2008.
48. Vyvanse [package insert]. Wayne, PA: Shire US, Inc; 2008.
49. Biederman J, Mick E, Surman C, et al. A randomized, placebo-controlled trial of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder. Biol Psychiatry. 2006;59(9):829-835.
50. Medori R, Ramos-Quiroga JA, Casas M, et al. A randomized, placebo-controlled trial of three fixed dosages of prolonged-release OROS methylphenidate in adults with attention-deficit/hyperactivity disorder. Biol Psychiatry. 2008;63(10):981-989.
51. Chronis-Tuscano A, Seymour KE, Stein MA, et al. Efficacy of osmotic-release oral system (OROS) methylphenidate for mothers with attention-deficit/hyperactivity disorder (ADHD): preliminary report of effects on ADHD symptoms and parenting. J Clin Psychiatry. 2008;69(12):1938-1947.
52. Adler LA, Zimmerman B, Starr HL, et al. Efficacy and safety of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, double-blind, parallel group, dose-escalation study. J Clin Psychopharmacol. 2009;29(3):239-247.
53. Spencer TJ, Adler LA, McGough JJ, Muniz R, Jiang H, Pestreich L; Adult ADHD Research Group. Efficacy and safety of dexmethylphenidate extended-release capsules in adults with attention-deficit/hyperactivity disorder. Biol Psychiatry. 2007;61(12):1380-1387.
54. Adler LA, Spencer T, McGough JJ, Jiang H, Muniz R. Long-term effectiveness and safety of dexmethylphenidate extended-release capsules in adult ADHD. J Atten Disord. 2009;12(5)449-459.
55. Weisler RH, Biederman J, Spencer TJ, et al. Mixed amphetamine salts extended-release in the treatment of adult ADHD: a randomized, controlled trial. CNS Spectr. 2006;11(8):625-639.
56. Adler LA, Spencer T, Brown TE, et al. Once-daily atomoxetine for adult attention-deficit/hyperactivity disorder: a 6-month, double-blind trial. J Clin Psychopharmacol. 2009;29(1):44-50.
57. Adler LA, Goodman DW, Kollins SH, et al; 303 Study Group. Double-blind, placebo-controlled study of the efficacy and safety of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder. J Clin Psychiatry. 2008;69(9):1364-1373.
58. Weisler R, Young J, Mattingly G, Gao J, Squires L, Adler L. Long-term safety and efficacy of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder. Poster presented at: US Psychiatric and Mental Health Congress; October 30-November 2, 2008; San Diego, CA.
59. Brams M. Efficacy and safety of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder in the adult workplace environment. Paper presented at: Annual Meeting of the New Clinical Drug Evaluation Unit; June 29-July 2, 2009; Hollywood, FL.
60. Wilens TE, MeDermott SP, Biederman J, Abrantes A, Hahesy A, Spencer TJ. Cognitive therapy in the treatment of adults with ADHD: a systematic chart review of 26 cases. J Cognitive Psychother. 1999;13(3):215-226. (Pubitemid 30010794)
61. Safren SA, Otto MW, Sprich S, Winett CL, Wilens TE, Biederman J. Cognitive-behavioral therapy for ADHD in medication-treated adults with continued symptoms. Behav Res Ther. 2005;43(7):831-842.
62. Solanto MV, Marks DJ, Mitchell KJ, Wasserstein J, Kofman MD. Development of a new psychosocial treatment for adult ADHD. J Atten Disord. 2008;11(6):728-736.
63. Wilens TE, Biederman J, Prince J, et al. Six-week, double-blind, placebo-controlled study of desipramine for adult attention deficit hyperactivity disorder. Am J Psychiatry. 1996;153(9):1147-1153.
64. Hornig-Rohan M, Amsterdam JD. Venlafaxine versus stimulant therapy in patients with dual diagnosis ADD and depression. Prog Neuropsychopharmacol Biol Psychiatry. 2002;26(3):585-589. (Pubitemid 34252955)
65. Findling RL. Open-label treatment of comorbid depression and attentional disorders with co-administration of serotonin reuptake inhibitors and psychostimulants in children, adolescents, and adults: a case series. J Child Adolesc Psychopharmacol. 1996;6(3):165-175.
66. Weiss M, Hechtman L; Adult ADHD Research Group. A randomized double-blind trial of paroxetine and/or dextroamphetamine and problem-focused therapy for attention-deficit/hyperactivity disorder in adults. J Clin Psychiatry. 2006;67(4):611-619.
67. Wilens TE, Prince JB, Spencer T, et al. An open trial of bupropion for the treatment of adults with attention-deficit/hyperactivity disorder and bipolar disorder. Biol Psychiatry. 2003;54(1):9-16.